Jan 5 (Reuters) - Gene therapy firm Graphite Bio (GRPH.O), opens new tab said on Thursday it was pausing an early-to-mid-stage trial of its blood disease therapy due to a serious adverse event in the ...
The narrative around Graphite One has long been straightforward: build a mine in Alaska, process the material in Ohio, and help the US break free from China’s g ...
The Targets are the sole holders of the Nachu Graphite Project, a world-class, advanced-stage graphite development asset located in the Ruangwa District, Lindi Region of Southern Tanzania (the “ ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Gene therapy firm Graphite Bio said on Thursday it was pausing an early-to-mid-stage trial of its blood disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results